Hironao Wakabayashi earned M.D. after 6 year education at Fukushima Medical School in Japan on 1988. In the Department of Pathology (II) at Fukushima Medical School he enrolled Ph.D. program. He studied on cancer invasion and metastasis and earned Ph.D. at 1992. He obtained postdoctoral training at University of Texas MD Anderson Cancer Center in Huston working on the same subject until he had an appointment as a Research Assistant Professor at The Institute for Molecular Medicine at Irvine, CA on 1996. Since 1999 he has been working as a Research Assistant Professor in the Department of Biochemistry and Biophysics at University of Rochester studying on the structural and functional analyses of blood coagulation factor VIII.
Patient Care Bio
Hemophilia A is a bleeding disease caused by deficiency or defect of a protein called blood coagulation factor VIII. Since 1992 recombinant factor VIII product was introduced, the periodical (very frequent) supplement of this protein by injection through vein has been a major therapeutic approach. Our research focuses on the development of new factor VIII product which has better activity. Consequently the frequency of injection as well as a risk of heavy bleeding incident would be reduced. Hemophilia A patients are usually a boy. Less injection would be very helpful to ease them.
I started my career as a pathologist and obtained a training of cell biology and protein chemistry. I have been working on current study for 8 years.